CAMPATH-1 Antigen (CD52) Antibody (PE)

260€ (25 tests)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
CAMPATH-1 Antigen (CD52) Antibody (PE)
category
Primary Antibodies
provider
Abbexa
reference
abx413241
tested applications
FCM
Description
Cluster of Differentiation 52 (CD52) Antibody (PE) is a Rat Monoclonal antibody against Cluster of Differentiation 52 (CD52).
Documents del producto
Instrucciones
Data sheet
Product specifications
Category | Primary Antibodies |
Immunogen Target | CAMPATH-1 Antigen (CD52) |
Host | Rat |
Reactivity | Human |
Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Monoclonal |
Conjugation | PE |
Isotype | IgG2b |
Purification | Purified |
Size 1 | 25 tests |
Size 2 | 100 tests |
Form | Lyophilized |
Tested Applications | FCM |
Buffer | PBS, 0.09% NaN3, 1% BSA, 5% Sucrose. |
Availability | Shipped within 3-7 working days. |
Storage | Store at -20 °C or -80 °C. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
UniProt ID | P31358 |
Alias | HE5,CDW52,EDDM5,CAMPATH-1 antigen,Cambridge pathology 1,Epididymal secretory protein E5,Human epididymis-specific protein 5 |
Background | Antibody anti-CD52 |
Status | RUO |
Descripción
CD52 is a small glycoprotein predominantly expressed on the surface of mature lymphocytes (both T and B cells), monocytes, macrophages, eosinophils, and some epithelial cells of the reproductive system. The CD52 molecule plays an important role in regulating immune cell function, and its high expression on lymphocytes makes it a valuable therapeutic target in immunology and oncology, particularly in treatments for autoimmune diseases and certain types of leukemia, such as chronic lymphocytic leukemia (CLL). The precise function of CD52 remains somewhat unclear, although it is believed to be involved in modulating immune responses and cellular interactions. CD52 is the target of the monoclonal antibody alemtuzumab, a treatment used in autoimmune conditions like multiple sclerosis (MS) and certain cancers like CLL. Alemtuzumab binds to CD52 on the surface of immune cells and triggers their destruction through immune-mediated mechanisms, leading to immunosuppression. This therapeutic aspect has drawn attention to the biological and clinical significance of the CD52 molecule.
Related Products

Human CD52 (CAMPATH-1 antigen) ELISA Kit
Ver Producto
Human CD52 (CAMPATH-1 antigen) QuickTest ELISA Kit
Ver Producto